How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide
Authors:
Open Access
- 6 December 2019
- journal article
- conference paper
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 513-521
Abstract
HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell–replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.Keywords
This publication has 74 references indexed in Scilit:
- Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation CyclophosphamideTransplantation and Cellular Therapy, 2014
- HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow TransplantationTransplantation and Cellular Therapy, 2014
- Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow TransplantationSeminars in Oncology, 2012
- Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated DonorsNew England Journal of Medicine, 2012
- Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patientsJournal of Internal Medicine, 2012
- Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood graftsBlood, 2011
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on OutcomeTransplantation and Cellular Therapy, 2010
- High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell TransplantationTransplantation, 2009
- Loss of Mismatched HLA in Leukemia after Stem-Cell TransplantationNew England Journal of Medicine, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008